A Systematic Review of the Effects of Hormone Therapy on Psychological Functioning and Quality of Life in Transgender Individuals.
White Hughto JM, Reisner SL. · 2016
Read A Systematic Review of the Effects of Hormone Therapy on Psychological Functioning and Quality of Life in Transgender Individuals. by White Hughto JM, Reisner SL. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5010234.txt.
Introduction
Jaclyn M. White Hughto and Sari L. Reisner review hormone therapy and mental health in transgender people, in Transgender Health in 2016. Transgender people face high rates of depression and anxiety, and many seek hormone therapy as part of transition. The review searched major databases to November 2014 for studies that followed people over time after starting hormones.
Only three studies fit, covering 247 adults, none with a comparison group. Two found clear gains in mental health at three to six months and at twelve months after starting therapy. The third found better quality of life at twelve months, though the gain reached clear statistical support only in male-to-female participants. The authors stress that the proof is weak in design, and they call for controlled long-term trials to test these hopeful early signs.
Catalog record
| CREATOR | White Hughto JM, Reisner SL. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 38 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
A Systematic Review of the Effects of Hormone Therapy on Psychological Functioning and Quality of Life in Transgender Individuals By Jaclyn M White Hughto, Sari L Reisner Published in: Transgender Health DOI: 10.1089/trgh.2015.0008 ABSTRACT Abstract Objectives: To review evidence from prospective cohort studies of the relationship between hormone therapy and changes in psychological functioning and quality of life in transgender individuals accessing hormone therapy over time. Data Sources: MEDLINE, PsycINFO, and PubMed were searched for relevant studies from inception to November 2014. Reference lists of included studies were hand searched. Results: Three uncontrolled prospective cohort studies, enrolling 247 transgender adults (180 male-to-female [MTF], 67 female-to-male [FTM]) initiating hormone therapy for the treatment of gender identity disorder (prior diagnostic term for gender dysphoria), were identified. The studies measured exposure to hormone therapy and subsequent changes in mental health (e.g., depression, anxiety) and quality of life outcomes at follow-up. Two studies showed a significant improvement in psychological functioning at 3–6 months and 12 months compared with baseline after initiating hormone therapy. The third study showed improvements in quality of life outcomes 12 months after initiating hormone therapy for FTM and MTF participants; however, only MTF participants showed a statistically significant increase in general quality of life after initiating hormone therapy. Conclusions: Hormone therapy interventions to improve the mental health and quality of life in transgender people with gender dysphoria have not been evaluated in controlled trials. Low quality evidence suggests that hormone therapy may lead to improvements in psychological functioning. Prospective controlled trials are needed to investigate the effects of hormone therapy on the mental health of transgender people. Key words: : clinical care, gender dysphoria, gender transition, mental health, transgender INTRODUCTION Transgender people have a gender identity or expression that differs from their sex assigned at birth. Research documents high prevalence of depression, anxiety, and suicidal ideation among transgender individuals relative to the general population.1–3 Many transgender people experience psychological distress related to the discrepancy between their birth sex and felt a sense of being male, female, or otherwise gender nonconforming.4 Some individuals experience gender-related psychological distress at such an extreme level that their distress meets criteria for a formal psychiatric diagnosis—Gender Dysphoria.4 The critical element of gender dysphoria is the presence of clinically significant distress associated with the strong and persistent difference between one's expressed/experienced gender and one's sex assigned at birth.5 The World Professional Association of Transgender Health's Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People (Version 7) lists social transition (living full or part-time in one's gender identity), psychotherapy, surgery, and hormone therapy as treatment options for individuals with gender dysphoria.6 While each person's treatment plan is individualized, and may include one or multiple interventions, hormone therapy is generally the first medical intervention accessed by individuals with gender dysphoria who seek to masculinize or feminize their body to be consistent with their gender identity.6 Feminizing or masculinizing hormone therapy is the administration of exogenous endocrine agents to induce changes in physical appearance.6 Since hormone therapy is inexpensive relative to surgery and highly effective in the development of secondary sex characteristics (e.g., facial and body hair in female-to-male [FTM] individuals or breast tissue in male-to-females [MTFs]), hormone therapy is often the first, and sometimes only, medical gender affirmation intervention accessed by transgender individuals looking to develop masculine or feminine characteristics consistent with their gender identity. In some cases, hormone therapy may be required before surgical interventions can be conducted.6 Changing one's physical characteristics through hormone therapy is considered medically necessary for many transgender individuals and may relieve the psychological distress associated with gender dysphoria, reduce psychiatric comorbidities, and improve patients' quality of life.6 The efficacy of hormone therapy in relieving psychiatric distress related to gender dysphoria has largely been inferred through clinical practice and low quality evidence.7 In 2008, the first systematic review exploring the relationship between hormone therapy and the mental health of transgender individuals was conducted.7 Published in 2010, the review found that hormone therapy in individuals with gender identity disorder (the DSM-IV diagnostic name for gender dysphoria) likely improves gender dysphoria, psychological function, comorbidities (e.g., depression, anxiety, and suicidality), sexual functioning, and overall quality of life.7 However, the quality of the empirical evidence was very low. All of the reviewed studies pertaining to psychological functioning were nonrandomized and largely cross-sectional designs. Moreover, the majority of the studies evaluated hormone therapy in concert with sex reassignment surgery and so an evaluation of the specific relationship between hormone therapy and the psychological functioning of transgender individuals independent of surgical interventions was not possible. Since 2008, several higher quality studies exploring the relationship between hormone therapy and psychological functioning in transgender individuals have been published, thus an updated systematic evaluation of the research literature is warranted. The primary objectives of this review were to locate and describe studies examining the relationship between hormone therapy and the psychological functioning of transgender individuals; determine the risk of experiencing psychiatric distress in transgender individuals receiving hormone therapy compared with those not receiving hormone therapy or the general population; examine whether transgender individuals with poor mental health experience an improvement in their mental health status after the initiation of a hormone regimen; and assess whether any differences in the strength and direction of the association between hormone therapy and psychological functioning exist by gender identity (i.e., for MTF vs. FTM subjects). Additionally, the review aimed to assess the strength of evidence showing a relationship between hormone therapy and healthy psychological functioning in transgender individuals and identify future research and clinical practice needs. METHODS PRISMA8 reporting guidelines were used in the development of this protocol-driven report. The protocol was not published, but is available upon request. Eligibility criteria Studies were eligible for this review if they enrolled transgender or transsexual (or another term used to describe individuals with a gender identity different from their assigned sex at birth) individuals who were seeking hormone therapy to masculinize or feminize the body. All participants had been diagnosed with having gender identity disorder (prior diagnostic name for gender dysphoria). Because the goal was to assess changes in psychological functioning and quality of life after initiating hormone therapy, only studies with a longitudinal design were included in the review. No randomized controlled trials were identified. All included studies were nonrandomized (observational) and uncontrolled, prospective cohort studies. One-time cross-sectional studies, single case reports, case series, review articles, commentaries, letters, and studies that did not contain original data were excluded. Studies were included regardless of sample size. Only English language publications were included in the search. Studies following participants for less than 3 months were excluded. Interventions were limited to the administration of feminizing or masculinizing hormone therapy. Due to the wide variation of doses and types of hormones, all forms of hormone administration (e.g., self or provider injection, oral pill, intramuscular, transdermal patch or gel, or subcutaneous implant), dosing levels, dose frequency, and types (e.g., estrogen, androgen-reducing medications, progestins, testosterone, bioidentical, and compounded hormones) were included. Psychiatric disorders (DSM diagnosis or clinically significant symptomology), general psychological functioning, and general quality of life outcomes were assessed. Study identification The first author consulted an expert reference librarian to design and conduct the electronic search strategy with